Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Recombinant human C1 inhibitor"'
Publikováno v:
Journal of Investigational Allergology and Clinical Immunology. 31:255-256
Autor:
Hilary Longhurst, Henriette Farkas
Publikováno v:
Expert opinion on biological therapy. 20(5)
Introduction: Hereditary angioedema, a disabling condition, with high mortality when untreated, is caused by C1 inhibitor deficiency and other regulatory disorders of bradykinin production or metab...
Autor:
Kinga Viktória Kőhalmi, Henriette Farkas, Noémi Andrási, Lilian Varga, György Temesszentandrási, Nóra Veszeli, Ágnes Holdonner
Publikováno v:
International immunopharmacology. 80
OBJECTIVE Conestat alpha, a C1-inhibitor produced by recombinant technology (rhC1-INH) is an acute treatment for edematous attacks occurring in hereditary angioedema (HAE) with C1-inhibitor deficiency (C1-INH-HAE). Our study evaluated the efficacy an
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anurag Relan, L. Bellizzi, Anna Valerieva, Maria Staevska, Katarina Hrubiskova, Milos Jesenak, Henriette Farkas, Marco Cicardi, Andrea Zanichelli, Roman Hakl
Publikováno v:
Annals of Allergy, Asthma & Immunology. 119:S47-S48
Publikováno v:
Journal of Allergy and Clinical Immunology. 141:AB49
Publikováno v:
Journal of Allergy and Clinical Immunology. 141:AB56
Autor:
Maria Staevska, Anna Valerieva
Publikováno v:
Journal of Allergy and Clinical Immunology. 141:AB58
Autor:
Lilian Varga, Henriette Farkas
Publikováno v:
Expert Review of Clinical Immunology. 4:653-661
Hereditary and acquired angioedema are of outstanding clinical importance, as edematous attacks associated with these conditions can thrust afflicted patients into mortal danger. Currently, C1 inhibitor concentrate - a human blood product - is availa
Autor:
Frank Pieper, Johannes F.G. Vliegenthart, Johannis P. Kamerling, Patrick Van Berkel, Kate Koles, Maurice L.M. Mannesse, Jan H. Nuijens
Publikováno v:
Glycobiology. 14:51-64
Human C1 inhibitor (hC1INH) is a therapeutic N, O-glycoprotein with a growing number of clinical applications, but the current natural supplies are not likely to meet the clinical demands. Therefore, recombinant approaches are of interest, whereby sp